TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment.
Miso ParkDa-Sol KuenJaewoo ParkMunkyung ChoiYeonji KimEun Chae RohYong June ChoiYoon Gyoon KimYeonseok ChungSung Yun ChoKeon Wook KangPublished in: Journal for immunotherapy of cancer (2023)
The activated TYRO3-CCN1 axis in cancer could dampen anti-PD-1 therapy responses. These findings highlight the potential of TYRO3 blockade to improve the clinical outcomes of anti-PD-1 therapy.